Overview
Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2022-11-30
2022-11-30
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to assess the relationship between brain malignancy volume as defined by post-contrast T1 weighted and F18 Fluciclovine before and following LITT. We hypothesize that imaging with F18 Fluciclovine will be superior to anatomic MR imaging in lesion volume assessment before treatment and that residual F18 Fluciclovine defined tumor will predict local post-LITT disease recurrence.Phase:
Early Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
M.D. Anderson Cancer Center
Criteria
Inclusion Criteria- An adult patient with suspected or pathology-proven central nervous system neoplasm.
- MRI of the brain, positive for at least one intra-axial lesion greater than 5 mm.
Exclusion Criteria
- Contraindication to MR imaging.
- Known allergy to gadolinium-based contrast agents.
- Renal failure as defined by a GFR less than 30 or the use of hemodialysis.
- Pregnant.
- Patients less than 18 years of age will be excluded.